Phio Pharmaceuticals appoints Dr. R. Todd Plott to Board of Directors

Phio Pharmaceuticals Corp.

Board size increased to six members; Dr. Plott appointed effective July 20, 2026 until 2026 annual meeting.
Dr. Plott is a board-certified dermatologist with 30+ years experience and former FDA advisory committee member.
He will receive standard non-employee director compensation and indemnification agreement.
Appointment supports advancement of PH-762 for squamous cell carcinoma, per CEO Robert Bitterman.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

R. Todd Plott

Director

PHIO · Phio Pharmaceuticals Corp.

Effective: 2026-07-20
Filed: July 21, 2026, 7:07 AM ET

Effective as of July 20, 2026, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Todd Plott was appointed as Director at Phio Pharmaceuticals Corp..

Action: appointed
Role: Director

Exact text from the filing

Effective as of July 20, 2026, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders.

View on SEC.gov

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001437749-26-023916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.